Financial Analysis: Artiva Biotherapeutics (ARTV) versus Its Peers

Artiva Biotherapeutics (NASDAQ:ARTV) is one of 616 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare Artiva Biotherapeutics to similar companies based on the strength of its institutional ownership, risk, profitability, valuation, analyst recommendations, earnings and dividends.

Insider and Institutional Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 13.4% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Artiva Biotherapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics’ peers have a beta of 1.02, indicating that their average share price is 2% more volatile than the S&P 500.

Earnings and Valuation

This table compares Artiva Biotherapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Artiva Biotherapeutics	$250,000.00	-$65.37 million	-1.61
Artiva Biotherapeutics Competitors	$1.01 billion	$78.22 million	7.92

Artiva Biotherapeutics’ peers have higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Artiva Biotherapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1	0	4	1	2.83
Artiva Biotherapeutics Competitors	7423	12772	38900	1249	2.56

Artiva Biotherapeutics presently has a consensus price target of $19.00, indicating a potential upside of 357.83%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 62.26%. Given Artiva Biotherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than its peers.

Profitability

This table compares Artiva Biotherapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-49.99%	-44.05%
Artiva Biotherapeutics Competitors	-910.75%	-117.02%	-28.85%

Summary

Artiva Biotherapeutics beats its peers on 8 of the 13 factors compared.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.